ArticleOncoTargets and therapy2026
Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: (m)FOLFOXIRI plus bevacizumab has improved outcomes in selected patients with metastatic colorectal cancer (mCRC), but data from Southeast Asia remain limited. This study evaluated survival outcomes and factors associated with progression-free survival (PFS) and overall survival (OS) among Vietnamese patients with mCRC receiving first-line mFOLFOXIRI plus bevacizumab. Methods: In this retrospective real-world cohort study, 76 patients with mCRC treated with first-line mFOLFOXIRI plus bevacizumab were included. Tumor response, early tumor shrinkage (ETS), depth of response (DpR), PFS and OS were assessed. Survival outcomes were estimated using the Kaplan-Meier method, and exploratory prognostic factors were analyzed using Cox proportional hazards models. Results: A total of 76 patients were included, with a median age of 59.5 years; 61.8% were male, 65.8% had left-sided tumors, and 46.1% had metastases in ≥2 organs. The objective response rate (ORR) was 73.7%, and the disease control rate (DCR) was 97.4%. ETS was achieved in 56.6% of patients, with a median DpR of 40.0%. Molecular profiling showed RAS mutations in 49.3%, BRAF V600E in 5.5%, and PIK3CA mutations in 9.6%. Median PFS was 14.9 months (95% CI, 10.3-19.4), and median OS was 27.0 months (95% CI, 12.4-41.7), with 12- and 24-month OS rates of 81.8% and 56.3%, respectively. In multivariable analysis, ETS remained independently associated with improved PFS (HR 0.36, 95% CI 0.19-0.67; P = 0.001) and OS (HR 0.25, 95% CI 0.11-0.61; P = 0.002). High tumor burden (≥2 metastatic organs) was independently associated with shorter PFS, while elevated baseline CA19-9 was independently associated with inferior OS. Conclusion: In this Vietnamese retrospective real-world cohort, first-line mFOLFOXIRI plus bevacizumab achieved clinically meaningful response and survival outcomes. ETS was independently associated with improved survival and may serve as a useful prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.